Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with Basiliximab
Abstract Introduction: Cardiac allograft vasculopathy (CAV) is a major limitation for long-term survival of patients undergoing heart transplantation (HT). Some immunosuppressants can reduce the risk of CAV. Objectives: The primary objective was to evaluate the variation in the volumetric growth of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Cardiologia (SBC)
2015-01-01
|
| Series: | Arquivos Brasileiros de Cardiologia |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2015005050063&lng=en&tlng=en |
| _version_ | 1818339177496838144 |
|---|---|
| author | Ricardo Wang Lidia Ana Zytynski Moura, Sergio Veiga Lopes Francisco Diniz Affonso da Costa Newton Fernando Stadler Souza Filho Tiago Luiz Fernandes Natália Boing Salvatti José Rocha Faria-Neto |
| author_facet | Ricardo Wang Lidia Ana Zytynski Moura, Sergio Veiga Lopes Francisco Diniz Affonso da Costa Newton Fernando Stadler Souza Filho Tiago Luiz Fernandes Natália Boing Salvatti José Rocha Faria-Neto |
| author_sort | Ricardo Wang |
| collection | DOAJ |
| description | Abstract Introduction: Cardiac allograft vasculopathy (CAV) is a major limitation for long-term survival of patients undergoing heart transplantation (HT). Some immunosuppressants can reduce the risk of CAV. Objectives: The primary objective was to evaluate the variation in the volumetric growth of the intimal layer measured by intracoronary ultrasound (IVUS) after 1 year in patients who received basiliximab compared with that in a control group. Methods: Thirteen patients treated at a single center between 2007 and 2009 were analyzed retrospectively. Evaluations were performed with IVUS, measuring the volume of a coronary segment within the first 30 days and 1 year after HT. Vasculopathy was characterized by the volume of the intima of the vessel. Results: Thirteen patients included (7 in the basiliximab group and 6 in the control group). On IVUS assessment, the control group was found to have greater vessel volume (120–185.43 mm3 vs. 127.77–131.32 mm3; p = 0.051). Intimal layer growth (i.e., CAV) was also higher in the control group (27.30–49.15 mm3 [∆80%] vs. 20.23–26.69 mm3 [∆33%]; p = 0.015). Univariate regression analysis revealed that plaque volume and prior atherosclerosis of the donor were not related to intima growth (r = 0.15, p = 0.96), whereas positive remodeling was directly proportional to the volumetric growth of the intima (r = 0.85, p < 0.001). Conclusion: Routine induction therapy with basiliximab was associated with reduced growth of the intima of the vessel during the first year after HT. |
| first_indexed | 2024-12-13T15:22:52Z |
| format | Article |
| id | doaj.art-1552d938480445b892ed58bf4ac7ae54 |
| institution | Directory Open Access Journal |
| issn | 1678-4170 |
| language | English |
| last_indexed | 2024-12-13T15:22:52Z |
| publishDate | 2015-01-01 |
| publisher | Sociedade Brasileira de Cardiologia (SBC) |
| record_format | Article |
| series | Arquivos Brasileiros de Cardiologia |
| spelling | doaj.art-1552d938480445b892ed58bf4ac7ae542022-12-21T23:40:30ZengSociedade Brasileira de Cardiologia (SBC)Arquivos Brasileiros de Cardiologia1678-41702015-01-010000010.5935/abc.20150063S0066-782X2015005050063Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with BasiliximabRicardo WangLidia Ana Zytynski Moura,Sergio Veiga LopesFrancisco Diniz Affonso da CostaNewton Fernando Stadler Souza FilhoTiago Luiz FernandesNatália Boing SalvattiJosé Rocha Faria-NetoAbstract Introduction: Cardiac allograft vasculopathy (CAV) is a major limitation for long-term survival of patients undergoing heart transplantation (HT). Some immunosuppressants can reduce the risk of CAV. Objectives: The primary objective was to evaluate the variation in the volumetric growth of the intimal layer measured by intracoronary ultrasound (IVUS) after 1 year in patients who received basiliximab compared with that in a control group. Methods: Thirteen patients treated at a single center between 2007 and 2009 were analyzed retrospectively. Evaluations were performed with IVUS, measuring the volume of a coronary segment within the first 30 days and 1 year after HT. Vasculopathy was characterized by the volume of the intima of the vessel. Results: Thirteen patients included (7 in the basiliximab group and 6 in the control group). On IVUS assessment, the control group was found to have greater vessel volume (120–185.43 mm3 vs. 127.77–131.32 mm3; p = 0.051). Intimal layer growth (i.e., CAV) was also higher in the control group (27.30–49.15 mm3 [∆80%] vs. 20.23–26.69 mm3 [∆33%]; p = 0.015). Univariate regression analysis revealed that plaque volume and prior atherosclerosis of the donor were not related to intima growth (r = 0.15, p = 0.96), whereas positive remodeling was directly proportional to the volumetric growth of the intima (r = 0.85, p < 0.001). Conclusion: Routine induction therapy with basiliximab was associated with reduced growth of the intima of the vessel during the first year after HT.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2015005050063&lng=en&tlng=enDoenças Vasculares / fisiopatologiaTransplante CardíacoAnticorpos Monoclonais Murinos / administração & dosagemImunossupressores |
| spellingShingle | Ricardo Wang Lidia Ana Zytynski Moura, Sergio Veiga Lopes Francisco Diniz Affonso da Costa Newton Fernando Stadler Souza Filho Tiago Luiz Fernandes Natália Boing Salvatti José Rocha Faria-Neto Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with Basiliximab Arquivos Brasileiros de Cardiologia Doenças Vasculares / fisiopatologia Transplante Cardíaco Anticorpos Monoclonais Murinos / administração & dosagem Imunossupressores |
| title | Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with Basiliximab |
| title_full | Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with Basiliximab |
| title_fullStr | Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with Basiliximab |
| title_full_unstemmed | Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with Basiliximab |
| title_short | Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with Basiliximab |
| title_sort | reduced progression of cardiac allograft vasculopathy with routine use of induction therapy with basiliximab |
| topic | Doenças Vasculares / fisiopatologia Transplante Cardíaco Anticorpos Monoclonais Murinos / administração & dosagem Imunossupressores |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2015005050063&lng=en&tlng=en |
| work_keys_str_mv | AT ricardowang reducedprogressionofcardiacallograftvasculopathywithroutineuseofinductiontherapywithbasiliximab AT lidiaanazytynskimoura reducedprogressionofcardiacallograftvasculopathywithroutineuseofinductiontherapywithbasiliximab AT sergioveigalopes reducedprogressionofcardiacallograftvasculopathywithroutineuseofinductiontherapywithbasiliximab AT franciscodinizaffonsodacosta reducedprogressionofcardiacallograftvasculopathywithroutineuseofinductiontherapywithbasiliximab AT newtonfernandostadlersouzafilho reducedprogressionofcardiacallograftvasculopathywithroutineuseofinductiontherapywithbasiliximab AT tiagoluizfernandes reducedprogressionofcardiacallograftvasculopathywithroutineuseofinductiontherapywithbasiliximab AT nataliaboingsalvatti reducedprogressionofcardiacallograftvasculopathywithroutineuseofinductiontherapywithbasiliximab AT joserochafarianeto reducedprogressionofcardiacallograftvasculopathywithroutineuseofinductiontherapywithbasiliximab |